Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | CTSK | P43235 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13688706 | 1.00 | CASP3 (0.57) | CASP3CTSKKMT2AEPHX2TLR2 | |
| SCHEMBL1784323 | 1.00 | CASP3 (0.57) | CASP3CTSKKMT2AEPHX2TLR2 | |
| SCHEMBL13652765 | 0.93 | CTSK (0.60) | CASP3CTSK | |
| SCHEMBL16915242 | 0.93 | CTSK (0.60) | CASP3CTSK | |
| SCHEMBL10187000 | 0.91 | CASP3 (0.60) | CASP3CTSKKMT2AEPHX2 | |
| SCHEMBL13570148 | 0.91 | CASP3 (0.60) | CASP3CTSKKMT2AEPHX2 | |
| SCHEMBL16915227 | 0.91 | CTSK (0.55) | CASP3CTSKKMT2ATLR2 | |
| SCHEMBL18241728 | 0.91 | CTSK (0.55) | CASP3CTSKKMT2ATLR2 | |
| SCHEMBL29352794 | 0.89 | CASP3 (0.55) | CASP3CTSKKMT2AEPHX2 | |
| SCHEMBL27590333 | 0.88 | CASP3 (0.58) | CASP3KMT2AEPHX2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-RE43298-E1 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2011-05-19 | — | — | US | disclosed |
| EP-1481000-B1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-1385870-B1 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7592316-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2002008187-A9 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2003-01-03 | — | — | WO | disclosed |
| US-20020160962-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | MERCK SHARP & DOHME LLC | 2002-10-31 | — | — | US | disclosed |
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | DENDREON PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6376649-B1 | REACTING A N-TERMINALLY BLOCKED AMINOALDEHYDE WITH AN ISONITRILE AND A CARBOXYLIC ACID TO GIVE AN AMINO-ALPHA-ACYLOXYCARBOXAMIDE; REMOVING THE ACYLOXY GROUP, OR REMOVING THE PROTECTING GROUP GIVE THE DERIVATIVE. | CORVAS INTERNATIONAL, INC. | 2002-04-23 | — | — | US | disclosed |
| WO-2002008244-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002008187-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002008251-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | CORVAS INTERNATIONAL, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2002008256-A2 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-1140854-A2 | METHODS FOR THE SYNTHESIS OF ALPHA-HYDROXY-BETA-AMINO ACID AND AMIDE DERIVATIVES | CORVAS INTERNATIONAL, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035868-A2 | METHODS FOR THE SYNTHESIS OF ALPHA-HYDROXY-BETA-AMINO ACID AND AMIDE DERIVATIVES | CORVAS INTERNATIONAL, INC. (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068702-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, TMPRSS15, TMPRSS11D | CASP3 389/4885CTSK 305/4885KMT2A 3141/4885 |
| US-20020160962-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | VIP, HPN, HAVCR2 | CASP3 323/4885CTSK 244/4885KMT2A 3594/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | CASP3 282/4885CTSK 243/4885KMT2A 3449/4885 |
| US-20110117057-A1 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | HPN, TMPRSS15, VIP | CASP3 282/4885CTSK 243/4885KMT2A 3449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.